* Strong early efficacy signals * Solid cost control * Fair value range lifted to SEK 0.1-11.0/sh (SEK 0.1-10.5/sh)
ANNONS
Strong early efficacy signals
Last week, Isofol reported encouraging preliminary Phase 1b findings, with disease control in all evaluated patients, tumour shrinkage in a clear majority and reductions in tumour diameters of up to ~50%. Half of the patients became candidates for surgery with curative intent, a notable finding as surgery is usually not considered feasible in this population. Only one has experienced disease progression following an initial response and stable disease. No dose-limiting toxicities have been observed. Three patients remain to be enroled at the highest dose of 500 mg/m² in Phase 1b. The randomised Phase 2 with 60 patients and broader inclusion criteria, is planned across 15-20 EU sites, alongside a parallel Japanese bridging trial with 27 patients. We now expect Phase 2 to start in early Q1'27e.
Solid cost control
For Q3, opex was below our forecast at SEK 13m (vs. ABGSCe at SEK 16m). Beyond incorporating a SEK/USD tailwind, our main estimate revision is a roughly six-month delay vs. the timeline in our IOC, reflecting a longer recruitment period for Phase 1b. Cash and cash equiv. was SEK 98m (SEK 115m at Q2'26-end). Excl. proceeds from the TO2 warrants, Isofol expects its existing cash to fund operations for the next 12 months. As before, incl./excl. the TO2 warrants, we estimate a cash runway into '28e/late '27e, respectively.
Fair value range lifted to SEK 0.1-11.0/sh
In sum, our estimate revisions, incl. lower expected dilution following the share price increase, raise our fair value range to SEK 0.1-11.0/sh (0.1-10.5/sh). The risk-weighted scenario B yields a value of SEK 2.1/sh (SEK 1.8/sh). Scenario A, which assumes clinical failure (LOA: 0%), yields SEK 0.1/sh, while scenario C, which assumes full clinical and commercial success in 1L mCRC (LOA: 100%), yields SEK 11.0/sh (SEK 10.5/sh).